6C4B

ICD-11 MMS 2026-01

Disorders due to use of volatile inhalants

Description

Disorders due to use of volatile inhalants are characterised by the pattern and consequences of volatile inhalant use. Volatile inhalants include a range of compounds that are in the gaseous or vapour phase at ambient temperatures and include various organic solvents, glues, gasoline (petrol), nitrites and gases such as nitrous oxide, trichloroethane, butane, toluene, fluorocarbons, ether and halothane. They have a range of pharmacological properties but are predominantly central nervous system depressants, with many also having vasoactive effects. They tend to be used by younger persons and may be used when access to alternative psychoactive substances is difficult or impossible. Volatile Inhalant Intoxication is well recognized. Volatile inhalants have dependence-producing properties and Volatile Inhalant Dependence and Volatile Inhalant Withdrawal is recognized although comparatively uncommon worldwide. Volatile Inhalant-Induced Mental Disorders are described. They may also cause neurocognitive impairment, including Dementia.

Excludes

  • 6D72.13 – Amnestic disorder due to use of volatile inhalants

Exclusions from above levels

  • QE62 – Uncomplicated bereavement
  • QE84 – Acute stress reaction

Child codes

  • 6C4B.0 – Episode of harmful use of volatile inhalants
  • 6C4B.1 – Harmful pattern of use of volatile inhalants
  • 6C4B.2 – Volatile inhalant dependence
  • 6C4B.3 – Volatile inhalant intoxication
  • 6C4B.4 – Volatile inhalant withdrawal
  • 6C4B.5 – Volatile inhalant-induced delirium
  • 6C4B.6 – Volatile inhalant-induced psychotic disorder
  • 6C4B.7 – Certain specified volatile inhalants-induced mental or behavioural disorders
  • 6C4B.Y – Other specified disorders due to use of volatile inhalants
  • 6C4B.Z – Disorders due to use of volatile inhalants, unspecified

Sibling codes

  • 6C40 – Disorders due to use of alcohol
  • 6C41 – Disorders due to use of cannabis
  • 6C42 – Disorders due to use of synthetic cannabinoids
  • 6C43 – Disorders due to use of opioids
  • 6C44 – Disorders due to use of sedatives, hypnotics or anxiolytics
  • 6C45 – Disorders due to use of cocaine
  • 6C46 – Disorders due to use of stimulants including amphetamines, methamphetamine or methcathinone
  • 6C47 – Disorders due to use of synthetic cathinones
  • 6C48 – Disorders due to use of caffeine
  • 6C49 – Disorders due to use of hallucinogens
  • 6C4A – Disorders due to use of nicotine
  • 6C4C – Disorders due to use of methylene-dioxymethamphetamine [MDMA] or related drugs, including methylene-dioxyamphetamine [MDA]
  • 6C4D – Disorders due to use of dissociative drugs including ketamine or phencyclidine (PCP)
  • 6C4E – Disorders due to use of other specified psychoactive substances, including medications
  • 6C4F – Disorders due to use of multiple specified psychoactive substances, including medications
  • 6C4G – Disorders due to use of unknown or unspecified psychoactive substances
  • 6C4H – Disorders due to use of non-psychoactive substances
  • 6C4Y – Other specified disorders due to substance use
  • 6C4Z – Disorders due to substance use, unspecified

Foundation entity

Disorders due to use of volatile inhalants – http://id.who.int/icd/entity/1835610951

Allowed postcoordination axes

Part of: 06: Mental, behavioural or neurodevelopmental disorders